Electronic signatures misused during system upgrade – risk-based ERES remediation


Published on 30/01/2026

Addressing Misuse of Electronic Signatures During System Upgrades: A Regulatory Playbook

The use of electronic signatures (e-signatures) is a fundamental aspect of regulatory compliance in pharmaceutical manufacturing, especially during system upgrades. However, misuse of e-signatures can lead to significant challenges in data integrity and regulatory submissions. This article provides an actionable playbook for pharmaceutical professionals to address these issues effectively. After reading, you will be equipped to identify signs of misuse, analyze root causes, and implement corrective actions to ensure compliance with Good Distribution Practice (GDP) and ALCOA+ principles.

If you want a complete overview with practical prevention steps, see this Electronic Records & Electronic Signatures (ERES).

This playbook will guide production, quality control (QC), quality assurance (QA), engineering, and regulatory affairs (RA) professionals through a structured approach to tackle e-signature misuse, enhancing inspection readiness and maintaining data integrity in your systems.

Symptoms/Signals on the Floor or in the Lab

Identifying the symptoms of

electronic signature misuse can help mitigate potential compliance risks. Common signals may include:

  • Unusual Activity Logs: Reviewing user activity logs that show access to electronic records that are inconsistent or do not match user roles.
  • Signature Anomalies: Instances where e-signatures are found on unapproved documents or changes made without appropriate authorization.
  • Data Discrepancies: Observations of discrepancies between electronic records and physical records, which may indicate unauthorized alterations.
  • User Confusion: Reports from end-users regarding understanding e-signature procedures or discrepancies in training related to e-signature use.

Likely Causes

The root causes of e-signature misuse can be categorized into several domains:

Materials

Material issues may arise from the absence of clear guidelines or inadequate training materials that govern the use of e-signatures.

Pharma Tip:  Record retention failures during system operation – risk-based ERES remediation

Method

Improper methods of e-signature application, such as bypassing validation steps during system upgrades, can lead to misuse.

Machine

Technical failures in the electronic signature system or software bugs may facilitate unauthorized use or errors in recordkeeping.

Man

Human errors may include a lack of training on e-signature protocols, resulting in incorrect signing practices by personnel.

Measurement

Inadequate monitoring measures for user activities and lack of performance metrics may prevent the identification of suspicious activities.

Environment

Environmental factors such as stress or system overload during upgrades can contribute to rushed or erroneous operations related to e-signatures.

Immediate Containment Actions (first 60 minutes)

In the event of suspected misuse, it is critical to initiate immediate containment actions:

  • Isolate Affected Systems: Disconnect any affected components from the network to prevent further incidents.
  • Notify Key Stakeholders: Inform QA, RA, and IT teams about the situation to mobilize resources for investigation.
  • Secure Evidence: Collect system logs and relevant documentation for further investigation.
  • Implement Data Freeze: Temporarily halt all operations involving e-signatures until a thorough review is conducted.

Investigation Workflow

Once immediate containment actions are in place, a systematic investigation is essential. Follow these steps:

  1. Data Gathering: Collect all relevant records such as user access logs, audit trails, and e-signature usage statistics.
  2. Document Review: Assess the accuracy of documentation related to system updates and procedures surrounding e-signature use.
  3. Interviews: Conduct interviews with affected personnel to determine their understanding of the e-signature protocols.
  4. Assess Impact: Evaluate the potential impact of the misuse on data integrity and compliance with regulatory guidelines such as ALCOA+.

Root Cause Tools (5-Why, Fishbone, Fault Tree) and When to Use Which

Utilizing analytical tools to identify the root cause of e-signature misuse is critical. Here’s a breakdown of appropriate tools:

5-Why Analysis

This tool involves asking “why” repeatedly (typically five times) to dig deeper into the causal relationships. Use this when the problem appears straightforward but may have underlying complexities.

Pharma Tip:  Hybrid paper-electronic workflows uncontrolled during compliance audit – CAPA and revalidation strategy

Fishbone Diagram

This method helps in visualizing causes by categorizing them into various domains (the 6 Ms: Materials, Methods, Machines, Man, Measurement, and Environment). It is useful in group settings where multiple stakeholders contribute insights.

Related Reads

Fault Tree Analysis

This tool is best applied in technical environments to model the pathways leading to system failures. Use it when there is a need to assess the potential for system errors leading to e-signature misuse.

CAPA Strategy (Correction, Corrective Action, Preventive Action)

A comprehensive Corrective and Preventive Action (CAPA) strategy is crucial to maintain compliance:

Correction

Immediately correct any failed e-signature processes and remove any unauthorized signatures from records.

Corrective Action

Re-evaluate and revise training programs concerning e-signature protocols. Ensure that all personnel are aware of their obligations in terms of compliance and integrity.

Preventive Action

Implement robust validation measures for the e-signature system and schedule routine audits to preemptively catch possible areas of misuse.

Control Strategy & Monitoring (SPC/trending, sampling, alarms, verification)

Establishing a control strategy for monitoring e-signature use is essential:

  • Statistical Process Control (SPC): Utilize SPC techniques to monitor user access and signature activities.
  • Trending Analysis: Analyze trends in e-signature use patterns to identify anomalies early.
  • Sampling Strategies: Implement routine sampling of signed records for quality assessment.
  • Automated Alarms: Set up alerts for unauthorized access or unusual activity in e-signature workflows.
  • Verification Procedures: Regularly verify works against the documented procedures to ensure compliance.

Validation / Re-qualification / Change Control Impact (when needed)

A proper validation and change control strategy is imperative post-incident:

  • Validation of Changes: Ensure that any updates to the e-signature system maintain compliance and usability for the organization.
  • Documentation of Changes: Clearly document all changes along with validations to establish a clear audit trail.
  • Re-qualification: Consider re-qualifying impacted systems once corrective actions have been implemented to ensure they function correctly.
Pharma Tip:  Record retention failures during compliance audit – inspection evidence requirements

Inspection Readiness: What Evidence to Show

To demonstrate inspection readiness, ensure the following evidence is available:

  • Audit Trails: Access logs that show who signed what and when.
  • Documentation: Written procedures and policies on electronic signature use and handling.
  • Training Records: Records of staff training related to e-signature protocols.
  • Incident Reports: Documented reports of any incidents of misuse, along with corrective actions taken.
  • CAPA Documentation: Comprehensive records of the CAPA process and follow-up actions undertaken to resolve e-signature misuse.

FAQs

What constitutes misuse of electronic signatures?

Misuse of electronic signatures includes unauthorized access, incorrect use without proper authorization, or failure to follow established procedures.

How can we ensure data integrity in e-signature processes?

Implement robust training, regularly monitor e-signature use, and conduct routine audits to assess compliance with established protocols.

What are the regulatory implications of e-signature misuse?

Misuse can lead to non-compliance with regulatory guidelines such as ALCOA+, which may have serious implications including fines or product recalls.

What steps should be taken during a system upgrade?

During system upgrades, perform thorough validation of e-signature processes, ensure adequate training for users, and maintain open lines of communication about changes.

How often should we train staff on e-signature protocols?

Training should be conducted at least annually, or whenever there are changes to processes or regulatory requirements related to e-signatures.

What role does automation play in monitoring e-signatures?

Automation can significantly enhance monitoring capabilities by providing real-time alerts and tracking usage patterns effectively.

Can we use paper records alongside electronic signatures?

While mixed systems can exist, it is crucial to ensure that all records comply with regulatory guidelines to maintain data integrity.

How do we respond to an FDA inspection regarding e-signature compliance?

Be prepared to show documented evidence of compliance, training records, and a clear CAPA process in place addressing any recent issues.